8TH ANNUAL

North Carolina Research Triangle Pulmonary Hypertension Symposium

Friday, November 4, 2016

Hilton Durham near Duke University
3800 Hillsborough Road
Durham, NC 27705
Registration
Online registration and additional meeting information can be found at tinyurl.com/PulmonaryHTN2016

Registration fees
$195: MDs and DOs
$90: Non-Physician Clinicians or Allied Health
$80: Residents or Fellows
Registration fees include all symposium materials, breakfast, lunch and breaks.

Cancellation policy
All cancellation requests must be submitted in writing to Christy Darnell via email (christy.darnell@duke.edu). Registration cancellations received on or before September 30, 2016 will be fully refunded minus a processing fee of 5%. Cancellation requests submitted from October 1-22, 2016 will receive a 50% refund minus a processing fee of 5%. Cancellation requests received on or after October 23, 2016 will not be refunded. In the event that the program is cancelled or postponed, we will not be responsible for any travel costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies, or hotels.

Event contact
Christy Darnell
Duke Heart Center
Phone: 919-613-0988
Email: christy.darnell@duke.edu

Accommodations
A block of rooms has been reserved at the Hilton Durham near Duke University, 3800 Hillsborough Road, Durham, NC 27705. Rooms are $119 per night, plus applicable taxes. The room block will be held until October 18, 2016, but may sell out prior to this date. To reserve your room at the conference rate, please call 919-564-2900 and identify yourself as part of the 8th Annual NC Research Triangle Pulmonary Hypertension Symposium.

Joint accreditation statement
This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development for the advancement of patient care. In support of improving patient care, the Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 6.75 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Disclosure
The Duke University Health System Department of Clinical Education & Professional Development adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of CE. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

Resolution of conflicts of interest
In accordance with the ACCME Standards for Commercial Support of CME, and prior to the planning and implementation of this CME activity, the Duke University Health System Department of Clinical Education & Professional Development will implement mechanisms to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

Disclaimer
The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Special needs statement
The Duke University Health System Department of Clinical Education & Professional Development is committed to making its activities accessible to all individuals. If you need assistance or accommodation(s), please call and/or submit a description of your needs in writing to Christy Darnell via email (christy.darnell@duke.edu) or telephone (919-613-0988).

Commercial support acknowledgement
A complete list of supporters will be published in the course syllabus.
Faculty directors

H. James Ford, MD
Assistant Professor of Medicine
Director, Pulmonary Hypertension Center
University of North Carolina at Chapel Hill

Terry Fortin, MD
Assistant Professor of Medicine, Division of Cardiology
Division of Pulmonary, Allergy & Critical Care Medicine
Pulmonary Vascular Disease Center
Duke University Medical Center

Invited faculty

Richard Channick, MD
Director, Pulmonary Hypertension and Thromboendarterectomy Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School

Talal I. Dahhan, MD, MSEd
Medical Instructor,
Center for Pulmonary Vascular Disease,
Duke University Medical Center

Steven Kawut, MD, MS
Professor of Medicine and Epidemiology
Director, Pulmonary Vascular Disease Program
Perelman School of Medicine at the University of Pennsylvania

Martha Kingman Liberty, DNP, FNP-C
Nurse Practitioner Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas

Richard A. Krasuski, MD
Professor of Medicine and Pediatrics
Director of the Adult Congenital Heart Disease Center
Director of Hemodynamic Research
Duke University Medical Center

Sudarshan Rajagopal, MD
Assistant Professor of Medicine
Assistant Research Professor in Biochemistry
Duke University Medical Center

Lisa Rose-Jones, MD
Assistant Professor of Medicine
Pulmonary Hypertension Program
University of North Carolina at Chapel Hill

Ankoor Shah, MD
Assistant Professor of Medicine
Duke University Medical Center

Victor Test, MD
Professor of Medicine
Department of Medicine
Director, Pulmonary Vascular Disease Center
Duke University Medical Center

REGISTER NOW

tinyurl.com/PulmonaryHTN2016
<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>SPEAKERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–8:00 AM</td>
<td>Registration, Breakfast, and Exhibits</td>
<td></td>
</tr>
<tr>
<td>8:00–8:10 AM</td>
<td>Welcome and Introduction/Opening Remarks</td>
<td>H. James Ford, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Terry Fortin, MD</td>
</tr>
<tr>
<td>8:10–8:30 AM</td>
<td>PH Basics 2016</td>
<td>H. James Ford, MD</td>
</tr>
<tr>
<td>8:30–9:10 AM</td>
<td>Risks of Prostacyclin Therapy</td>
<td>Martha Kingman, DNP, FNP-C</td>
</tr>
<tr>
<td>9:10–9:40 AM</td>
<td>Anticoagulation in PAH: Yes or No?</td>
<td>Talal Dahhan, MD</td>
</tr>
<tr>
<td>9:40–10:10 AM</td>
<td>PAH Year in Review: Clinical Research</td>
<td>Victor Test, MD</td>
</tr>
<tr>
<td>10:10–10:25 AM</td>
<td>Break/Exhibits</td>
<td></td>
</tr>
<tr>
<td>10:25–11:05 AM</td>
<td>Drugs, Toxins, and PAH: Past and Present</td>
<td>Richard Channick, MD</td>
</tr>
<tr>
<td>11:05–11:35 AM</td>
<td>Congenital Heart Disease Associated PAH 2016 Update</td>
<td>Richard Krasuski, MD</td>
</tr>
<tr>
<td>11:35–12:05 PM</td>
<td>HFpEF and PH Is There a Role for PAH Therapy?</td>
<td>Lisa Rose-Jones, MD</td>
</tr>
<tr>
<td>12:05–1:10 PM</td>
<td>Lunch and Exhibits</td>
<td></td>
</tr>
<tr>
<td>1:10–1:50 PM</td>
<td>Gender/Sex Hormones and PAH</td>
<td>Steven Kawut, MD, MS</td>
</tr>
<tr>
<td>1:50–2:20 PM</td>
<td>PAH and Connective Tissue Disease</td>
<td>Ankoor Shah, MD</td>
</tr>
<tr>
<td>2:20–2:35 PM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
<tr>
<td>2:35–3:05 PM</td>
<td>Basic/Translational Research in PAH for the Practicing Clinician</td>
<td>Sudarshan Rajagopal, MD</td>
</tr>
<tr>
<td>3:05–3:35 PM</td>
<td>Non-pharmacologic Care of the PAH Patient</td>
<td>Terry Fortin, MD</td>
</tr>
<tr>
<td>3:35–4:20 PM</td>
<td>Case-based Presentations</td>
<td>Duke and UNC Fellows</td>
</tr>
<tr>
<td>4:20–4:30 PM</td>
<td>Symposium Recap and Closing Remarks</td>
<td>H. James Ford, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Terry Fortin, MD</td>
</tr>
</tbody>
</table>

Please note: Invited faculty and program are subject to change without notice.
Learning objectives

At the conclusion of this activity, participants should be able to:

- Describe the classification of Pulmonary Hypertension (PH) according to the Fifth World Symposium, as well as the basic tenets of PAH diagnosis.
- Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension (PAH) specific therapy, with a special focus on WHO Group 2 PH.
- Identify appropriate and reasonable treatment choices based on available evidence from recent clinical studies; and recognize the challenges associated with certain forms of PAH therapy.
- Recognize when treatment responses are suboptimal and when referral to a specialty center is appropriate.
- Describe the pharmacologic management of PAH patients, including the role of anticoagulation, gender, and associated diseases on treatment response and long term outcomes.
- Understand and describe novel compounds in development for the future treatment of PAH, as well as new basic science discoveries on the pathogenesis of the disease.
- Identify and employ important nonpharmacologic interventions in the management of PAH.

Target audience

This program is designed to meet the continuing education (CE) needs of pulmonologists, cardiologists, nurses, and other allied healthcare professionals involved in the treatment of pulmonary hypertension.

Statement of need

The field of pulmonary arterial hypertension (PAH) is rapidly developing with multiple new diagnosis and treatment therapies introduced in recent years. This has created an evolving learning curve for pulmonologists and cardiologists treating PAH, as well as primary care physicians and other allied health professionals who need to be kept abreast of ever-changing diagnostic and treatment paradigms, as well as current clinical guidelines. This dynamic state of pulmonary hypertension means there are constant gaps in provider knowledge of appropriate diagnostic procedures, proper treatment choices, and timing in advancement of care to pulmonary hypertension specialty centers. A general lack of familiarity with clinical guidelines highlights the need to improve diagnostic competence and treatment knowledge among all health care professionals who care for pulmonary hypertension patients.

Sponsored by:

DukeHealth

In collaboration with:

UNC School of Medicine

PHA Pulmonary Hypertension Association